Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-03-13 Management Reports
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Komunikat w zakresie rozwoju i wdrożenia wysokowydajnego testu qRT-PCR do diagnostyki zakażeń SARS-COV-2 - Content (PL)
Management Reports Classification · 1% confidence The document is a short announcement (1068 characters) written in Polish by the Management Board ('Zarząd Spółki'). It details a strategic decision made on March 13, 2020, regarding the adoption of BSL-3 zones and the implementation of qRT-PCR test manufacturing for diagnostics in new laboratories. It discusses the rationale (positive test results, business potential) and expected timeline (readiness before the autumn season). This content relates to strategic business development, operational changes, and future product/service implementation, rather than a formal financial report (like 10-K or IR), a specific regulatory filing, or a standard earnings release. Since it is a strategic update from management about future plans and capabilities, it best fits the 'Management Reports' (MDA) category, which covers management's explanation of business trends and outlook, even if this specific announcement is forward-looking rather than retrospective on financials. It is not a standard 'Regulatory Filing' (RNS) as it describes a specific internal strategic move.
2020-03-13 Polish
Zarekomendowanie przez NCBiR do dofinansowania projektu Spółki - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a formal announcement from the Management Board of Celon Pharma S.A. regarding the successful recommendation of their project application ('Serotoninergiczna terapia przeciwbólowa oparta o agonistę receptora 5-HT7 (STEP7)') for funding by the National Centre for Research and Development (NCBiR). It details the project cost (55.6 million PLN) and the recommended funding amount (36.2 million PLN). This type of announcement, concerning fundraising, grants, or significant financing activities related to R&D projects, aligns best with the 'Capital/Financing Update' category. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the focus on securing significant external funding for development, CAP is the most appropriate classification.
2020-03-05 Polish
Uzyskanie patentu w zakresie Inhibitorów kinazy PI3K na terenie Japonii - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement by the Management Board ('Zarząd') of Celon Pharma S.A. regarding the acquisition of a patent from the Japanese Patent Office for PI3K inhibitors used in treating immunological, inflammatory, and oncological diseases. This announcement details a specific corporate event related to intellectual property and R&D progress, which is not covered by standard financial reports (10-K, IR, ER) or routine administrative filings (DIV, DIRS). It is a specific update on corporate assets/development. Since there is no specific category for 'Patent Grant Announcement', and it is not a general regulatory filing (RNS) or a presentation (IP), it best fits under Capital/Financing Update (CAP) as it directly impacts the company's asset value and commercialization potential, or potentially as a general Regulatory Filing (RNS). Given the focus on IP protection which enhances commercial value, CAP is a possibility, but RNS is the most appropriate fallback for specific, non-standard corporate event disclosures not covered elsewhere. However, upon reviewing the definitions, none perfectly capture a patent grant announcement. It is a significant corporate development. Since it is not a financing event (CAP) or a legal proceeding (LTR), and it is a specific announcement, RNS (Regulatory Filings - general fallback) is the safest classification, although it is a very specific type of corporate news.
2020-02-19 Polish
Terminy przekazywania raportów okresowych w 2020 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text is very short (606 characters) and explicitly states the dates when various periodic reports (annual, quarterly, semi-annual) for the year 2020 will be released by the Management Board of Celon Pharma S.A. It cites a specific Polish Ministry of Finance regulation regarding current and periodic information disclosure. Since the document is merely announcing the schedule for future reports rather than containing the reports themselves, it fits the definition of a Report Publication Announcement (RPA), which covers announcements about the timing or release of other company reports. It is not the full report (10-K or IR), nor is it a general regulatory filing (RNS) because RPA is more specific.
2020-01-29 Polish
Aktualizacja informacji o wynikach toczących się sporów sądowych dotyczących sprzedaży leku Salmex w Polsce i na wybranych rynkach europejskich - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document text, written in Polish, discusses the resolution of lawsuits initiated by GlaxoSmithKline (GSK) against Celon Pharma S.A. regarding alleged trademark and copyright infringement related to inhaler products. It details the conclusion of these legal proceedings through a settlement agreement reached on January 12, 2020, which involves withdrawing from various court proceedings across several European markets. This content directly relates to significant lawsuits and regulatory/legal matters involving the company. Therefore, it fits the definition of a Legal Proceedings Report (LTR). The document is substantive and reports on the outcome, not just the announcement of a report.
2020-01-13 Polish
Złożenie wniosku o spotkanie konsultacyjne w FDA - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is very short (649 characters) and describes a specific action taken by the company (filing a request for a pre-IND meeting with the FDA) related to regulatory consultation and clinical development strategy for a drug (esketamine Celon DPI). This action is a specific regulatory step concerning the drug approval process, which is not explicitly covered by the main categories like 10-K, ER, or IR. It is not a general announcement of a report (RPA/RNS), but a specific regulatory update concerning legal/approval pathways. Given the options, this type of specific regulatory communication regarding drug development strategy and interaction with a regulatory body (FDA) fits best under the general 'Regulatory Filings' (RNS) category, as it is a specific, non-financial, non-management, non-dividend regulatory event that doesn't align with LTR (Legal Proceedings) or CAP (Financing). It is a regulatory update.
2019-12-21 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.